Differential effects of proteasome inhibitors on cell cycle and apoptotic pathways in human YT and Jurkat cells

Journal of Cellular Biochemistry

Volumn 97, Issue 1, 2006, Pages 122-134

  Lu, Min ^a   Dou, Q Ping ^b,c   Kitson, Richard P ^a,d   Smith, David M ^b,e   Goldfarb, Ronald H ^a,d  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c KARMANOS CANCER INSTITUTE   (United States)

^d Sopherion Therapeutics Inc   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Apoptosis; Inhibitor; NK cells; Proteasome

Indexed keywords

20S PROTEASOME; 26S PROTEASOME; CASPASE 3; EPIGALLOCATECHIN GALLATE; I KAPPA B ALPHA; LACTACYSTIN BETA LACTONE; N ACETYLLEUCYLLEUCYLNORLEUCINAL; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN P27; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL VIABILITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; T LYMPHOCYTE;

APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CASPASES; CELL CYCLE; CELL LINE; CYSTEINE PROTEINASE INHIBITORS; HUMANS; JURKAT CELLS; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 30044447015     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.20543     Document Type: Article

References (54)

1. An B, Goldfarb RH, Siman R, Dou QP. 1998. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ 5:1062-1075.
2. Awasthi N, Wagner BJ. 2004. Interferon-gamma induces apoptosis of lens alphaTN4-1 cells and proteasome inhibition has an antiapoptotic effect. Invest Ophthalmol Vis Sci 45:222-229.
3. Baumeister W, Walz J, Zuhl F, Seemuller E. 1998. The proteasome: paradigm of a self-compartmentalizing protease. Cell 92:367-380.
4. Beyette J, Mason GG, Murray RZ, Cohen GM, Rivett AJ. 1998. Proteasome activities decrease during dexamethasone-induced apoptosis of thymocytes. Biochem J 332: 315-320.
5. Blagosklonny MV, Wu GS, Omura S, el-Deiry WS. 1996. Proteasome-dependent regulation of p21WAF1/CIP1 expression. Biochem Biophys Res Commun 227:564-569.
6. Boyer SN, Wazer DE, Band V. 1996. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 56:4620-4624.
7. Brophy VA, Tavare JM, Rivett AJ. 2002. Treatment of COS-7 cells with proteasome inhibitors or gamma-interferon reduces the increase in caspase 3 activity associated with staurosporine-induced apoptosis. Arch Biochem Biophys 397:199-205.
8. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI, Slingerland JM. 1997. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer. Nat Med 3:227-230.
9. Chen P, Hochstrasser M. 1996. Autocatalytic subunit processing couples active site formation in the 20S proteasome to completion of assembly. Cell 86:961-972.
10. Chen F, Chang D, Goh M, Klibanov SA, Ljungman M. 2000. Role of p53 in cell cycle regulation and apoptosis following exposure to proteasome inhibitors. Cell Growth Differ 11:239-246.
11. Chuang SS, Kim MH, Johnson LA, Albertsson P, Kitson RP, Nannmark U, Goldfarb RH, Mathew PA. 2000. 2B4 stimulation of YT cells induces natural killer cell cytolytic function and invasiveness. Immunology 100: 378-383.
12. Coux O, Tanaka K, Goldberg AL. 1996. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 65:801-847.
13. Dallaporta B, Pablo M, Maisse C, Daugas E, Loeffler M, Zamzami N, Kroemer G. 2000. Proteasome activation as a critical event of thymocyte apoptosis. Cell Death Differ 7:368-373.
14. Darmon AJ, Bleackley RC. 1998. Proteases and cell-mediated cytotoxicity. Crit Rev Immunol 18:255-273.
15. Dick LR, Cruikshank AA, Grenier L, Melandri FD, Nunes SL, Stein RL. 1996. Mechanistic studies on the inactivation of the proteasome by lactacystin: A central role for clasio-lactacystin beta-lactone. J Biol Chem 271:7273-7276.
16. Dou QP, Goldfarb RH. 2002. Bortezomib: Millennium pharmaceuticals. IDrugs 5:828-834.
17. Emmerich NP, Nussbaum AK, Stevanovic S, Priemer M, Toes RE, Rammensee HG, Schild H. 2000. The human 26 S and 20 S proteasomes generate overlapping but different sets of peptide fragments from a model protein substrate. J Biol Chem 275:21140-21148.
18. Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, Schreiber SL. 1995. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 268:726-731.
19. Goldfarb RH. 1986. Role of neutral serine proteases in tumor cell lysis by natural killer cells (large granular lymphocytes) and activated macrophages. Semin Thromb Hemost 12:308-309.
20. Goldfarb RH, Wasserman K, Herberman RB, Kitson RP. 1992. Nongranular proteolytic enzymes of rat IL-2-activated natural killer cells. I. Subcellular localization and functional role. J Immunol 149:2061-2068.
21. Goldfarb RH, Basse P, Ohashi M, Kitson RP, Brunson KW. 1994. Preclinical studies of IL-2 activated natural killer effector cells for locoregional therapy of metastatic cancer. J Infus Chemother 4:77-82.
22. Green DR, Reed JC. 1998. Mitochondria and apoptosis. Science 281:1309-1312.
23. Grimm LM, Goldberg AL, Poirier GG, Schwartz LM, Osborne BA. 1996. Proteasomes play an essential role in thymocyte apoptosis. Embo J 15:3835-3844.
24. Grisham MB, Palombella VJ, Elliott PJ, Conner EM, Brand S, Wong HL, Pien C, Mazzola LM, Destree A, Parent L, Adams J. 1999. Inhibition of NF-kappa B activation in vitro and in vivo: Role of 26S proteasome. Methods Enzymol 300:345-363.
25. Groll M, Ditzel L, Lowe J, Stock D, Bochtler M, Bartunik HD, Huber R. 1997. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature 386:463-471.
26. Gross A, McDonnell JM, Korsmeyer SJ. 1999. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 13:1899-1911.
27. Heinemeyer W, Fischer M, Krimmer T, Stachon U, Wolf DH. 1997. The active sites of the eukaryotic 20 S proteasome and their involvement in subunit precursor processing. J Biol Chem 272:25200-25209.
28. Heusel JW, Wesselschmidt RL, Shresta S, Russell JH, Ley TJ. 1994. Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell 76:977-987.
29. Kamat AM, Karashima T, Davis DW, Lashinger L, Bar-Eli M, Millikan R, Shen Y, Dinney CP, McConkey DJ. 2004. The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther 3:279-290.
30. Kim OH, Lim JH, Woo KJ, Kim YH, Jin IN, Han ST, Park JW, Kwon TK. 2004. Influence of p53 and p21Waf1 expression on G2/M phase arrest of colorectal carcinoma HCT116 cells to proteasome inhibitors. Int J Oncol 24: 935-941.
31. Kisselev AF, Goldberg AL. 2001. Proteasome inhibitors: From research tools to drug candidates. Chem Biol 8: 739-758.
32. Kitson RP, Miller CA, Goldfarb RH. 1995. Non-granular proteolytic enzymes of rat interleukin-2-activated natural killer cells. III. Enhancement of A-NKP 1, 2, and 3 proteolytic activities (cleaving after Arg, Phe and Pro) in response to interleukin-2. Nat Immun 14:286-294.
33. Kitson RP, Lu M, Siman R, Goldfarb RH. 2000. Proteasome inhibitor and lymphocyte function: Partial inhibition of cell-mediated cytotoxicity and implication that the lymphocyte proteasome may contain multiple chymotryptic domains. In Vivo 14:265-268.
34. Lee DH, Goldberg AL. 1998. Proteasome inhibitors: Valuable new tools for cell biologists. Trends Cell Biol 8:397-403.
35. Li B, Dou QP. 2000. Bax degradation by the ubiquitin/ proteasome-dependent pathway: Involvement in tumor survival and progression. Proc Natl Acad Sci USA 97: 3850-3855.
36. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M. 1997. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 3:231-234.
37. Loidl G, Groll M, Musiol HJ, Huber R, Moroder L. 1999. Bivalency as a principle for proteasome inhibition. Proc Natl Acad Sci USA 96:5418-5422.
38. Lopes UG, Erhardt P, Yao R, Cooper GM. 1997. p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem 272:12893-12896.
39. Lu M, Kitson RP, Xue Y, Goldfarb RH. 2003. Activation of multiple caspases and modification of cell surface fas (CD95) in proteasome inhibitor-induced apoptosis of rat natural killer cells. J Cell Biochem 88:482-492.
40. Maki CG, Huibregtse JM, Howley PM. 1996. In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res 56:2649-2654.
41. Nam S, Smith DM, Dou QP. 2001. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem 276:13322-13330.
42. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M. 1995. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269:682-685.
43. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. 2005. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23:630-639.
44. Shinohara K, Tomioka M, Nakano H, Tone S, Ito H, Kawashima S. 1996. Apoptosis induction resulting from proteasome inhibition. Biochem J 317:385-388.
45. Tenev T, Marani M, McNeish I, Lemoine NR. 2001. Procaspase-3 overexpression sensitises ovarian cancer cells to proteasome inhibitors. Cell Death Differ 8:256-264.
46. Tomioka M, Sameshima M, Nakano H, Kubo T, Shinohora K, Seyama Y, Kawashima S, Tone S. 2002. A possible intermediate step during apoptotic execution. Hum Cell 15:43-51.
47. Toyoshima H, Hunter T. 1994. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78:67-74.
48. Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, Miyamoto S. 1995. Rel/NF-kappa B/I kappa B family: Intimate tales of association and dissociation. Genes Dev 9:2723-2735.
49. Voges D, Zwickl P, Baumeister W. 1999. The 26S proteasome: A molecular machine designed for controlled proteolysls. Annu Rev Biochem 68:1015-1068.
50. Wang Z, Su ZZ, Fisher PB, Wang S, VanTuyle G, Grant S. 1998. Evidence of a functional role for the cyclin-dependent kinase inhibitor p21(WAF1/CIP1/MDA6) in the reciprocal regulation of PKC activator-induced apoptosis and differentation in human myelomonocytic leukemia cells. Exp Cell Res 244:105-116.
51. Wasserman K, Kitson RP, Rivett AJ, Sweeney ST, Gabauer MK, Herberman RB, Watkins SC, Goldfarb RH. 1994. Nongranular proteolytic enzymes of rat IL-2-activated natural killer cells. II. Purification and identification of rat A-NKP 1 and A-NKP 2 as constituents of the multicatalytic proteinase (proteasome) complex. J Cell Biochem 55:133-145.
52. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP, Wang X. 1997. Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked. Science 275:1129-1132.
53. Yin D, Zhou H, Kumagai T, Liu G, Ong JM, Black KL, Koeffler HP. 2005. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene 24:344-354.
54. Zamzami N, Marchetti P, Castedo M, Decaudin D, Macho A, Hirsch T, Susin SA, Petit PX, Mignotte B, Kroemer G. 1995. Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. J Exp Med 182: 367-377.